Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations

BMC Cancer

Table 2 Demographic of PLD-treated patients

	BRCA1/2-Aberrant OC (n = 35)		Wild-Type OC (n = 76)		p-value
	No.	%	No.	%
Age at diagnosis, years
Median	55		64		<0.001^a
Range	39–77		41–82
Histology
HGS	34	97.1	70	92.1
Endometrioid	1	2.9	2	2.6
Clear Cell	0	0	2	2.6
Mucinous	0	0	0		0.429^b
LGS	0	0	0
Carcinosarcoma	0	0	2	2.6
FIGO stage at diagnosis
I	1	2.9	1	1.4
II	3	8.6	4	5.6
III	23	65.7	48	66.7	0.470^c
IV	8	22.9	19	26.4
NA	0	0	4
Debulking status
<2 cm	14	42.4	23	31.5	0.282^e
≥2 cm	19	57.6	50	68.5
NA	2		3
Platinum sensitivity at PLD initiation
Sensitive	5	15.2	9	12.5
Resistant	28	84.8	63	87.5	0.761^d
NA	2		4
No. of chemotherapy lines prior to PLD
≤2	25	71.4	61	80.3	0.429^e
>2	10	28.6	15	19.7
Evaluable for PLD response
Evaluable	26	74.3	61	80.3	0.644^e
Not evaluable	9	15.7	15	19.7

^aWelch Two Sample t-test; ^bFisher’s exact test, HGS versus non-HGS histology; ^cFisher’s exact test, early (I-II) versus advanced (III-IV) stage at diagnosis; ^dFisher’s exact test; ^eChi-squared test; NA, not available